Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Buy" from Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus recommendation of "Buy" from the ten research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $65.00.

A number of research firms have recently weighed in on VERA. Wedbush dropped their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Guggenheim reissued a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Cantor Fitzgerald lowered their target price on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and set a $85.00 target price (up from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Finally, Scotiabank reissued an "outperform" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd.

Vera Therapeutics Stock Down 1.1%

Shares of NASDAQ VERA traded down $0.25 during mid-day trading on Tuesday, reaching $23.51. The company had a trading volume of 312,736 shares, compared to its average volume of 995,413. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a debt-to-equity ratio of 0.10, a quick ratio of 27.68 and a current ratio of 27.68. The stock has a market capitalization of $1.50 billion, a PE ratio of -7.82 and a beta of 1.19. The stock's 50 day moving average is $22.75 and its 200-day moving average is $27.03.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period last year, the business earned ($0.56) EPS. As a group, equities analysts anticipate that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other news, Director Patrick G. Enright acquired 40,607 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was bought at an average price of $22.35 per share, with a total value of $907,566.45. Following the completion of the acquisition, the director owned 3,596,593 shares in the company, valued at approximately $80,383,853.55. This represents a 1.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 16.30% of the company's stock.

Institutional Trading of Vera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GC Wealth Management RIA LLC acquired a new stake in shares of Vera Therapeutics in the second quarter valued at approximately $320,000. Perigon Wealth Management LLC acquired a new stake in shares of Vera Therapeutics in the second quarter valued at approximately $245,000. Fifth Third Bancorp acquired a new stake in shares of Vera Therapeutics in the second quarter valued at approximately $102,000. Rhumbline Advisers increased its holdings in shares of Vera Therapeutics by 7.9% in the first quarter. Rhumbline Advisers now owns 63,189 shares of the company's stock valued at $1,518,000 after purchasing an additional 4,600 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company's stock valued at $999,000 after purchasing an additional 62,678 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.